Leveraging Connected TV for Effective Healthcare Advertising

Connected TV is becoming the most practical way for healthcare brands to buy television audiences with digital-style control, but only if they treat it like regulated TV from the start. For healthcare and pharma marketers, the shift is already obvious in the media mix: EMARKETER forecasts $5.56 billion in linear TV spending for healthcare and pharma in 2025 versus $10.63 billion in digital nonmobile spending that includes CTV, a sign that streaming inventory is no longer a side test but a central planning line item (EMARKETER).

That is the big answer for anyone searching connected TV healthcare or CTV advertising pharma strategy right now: CTV gives you TV-scale storytelling with better audience targeting, better measurement, tighter frequency control, and sharper geographic precision than linear TV, while still carrying the same FDA risk-presentation obligations that apply to television-format prescription drug ads (EMARKETER, FDA guidance, FDA announcement).

Table of Contents

• What connected TV means for healthcare brands right now
• CTV vs linear TV for pharma and MedTech
• How FDA fair balance applies to CTV ads
• A 6-step CTV launch framework for pharma teams
• Platform breakdown: where healthcare brands actually buy
• Compliance considerations beyond the ad itself
• Measurement and attribution: how CTV proves value
• Common pitfalls in connected TV healthcare campaigns
• FAQ
• Why XDS Health is built for this channel

What connected TV means for healthcare brands right now

Connected TV is streaming TV inventory bought on internet-connected televisions and TV devices rather than through traditional broadcast or cable schedules. In practical terms, that means placements inside environments such as Hulu, Roku, Disney+, Peacock, Netflix’s ad-supported tier, Tubi, Pluto TV, and YouTube watched on the living-room screen.

Why should pharma and MedTech marketers care now? Because CTV lets you keep what television still does well, namely reach, sight-sound-motion storytelling, and household-level awareness, while adding controls that brand teams have wanted from TV for years.

With linear TV, you still buy broad audiences, broad dayparts, and broad assumptions. With CTV, you can build around first-party audiences, behavior, household traits, content environments, and geography in a way that feels much closer to paid social or paid search planning than classic broadcast buying.

That matters in healthcare because healthcare journeys are rarely broad and simple. A patient audience can be defined by age, treatment stage, insurance context, comorbidity patterns, caregiver behavior, condition interest, or regional access. A MedTech audience may need a market-by-market launch strategy around health systems, procedure volume, or referral concentration. CTV is better suited to that level of nuance than a blunt age-and-program buy.

It also matters because healthcare teams are under pressure to prove more than reach. The IAB’s current CTV measurement framework centers core concepts such as impressions, viewability, reach, frequency, and attention, specifically because the market now expects streaming TV to be measured with more consistency and accountability than legacy TV ever delivered (IAB guidance).

For healthcare marketers, the result is simple: CTV is no longer just a shiny digital video add-on. It is becoming the operational layer that makes TV buying more precise, more accountable, and easier to optimize.

If you are planning by audience rather than by media silo, it also fits neatly into the broader life sciences split between patient and HCP journeys. We covered that audience design challenge in our guide to HCP vs. patient marketing strategy in life sciences, and the same principle applies here: build the media plan around who needs to move, not around legacy channel definitions.

CTV vs linear TV for pharma and MedTech

Here is the short version: linear still gives you scale, cultural moments, and older-skewing mass reach. CTV gives you control.

The budget story is moving in the same direction. EMARKETER says healthcare and pharma marketers are shifting ad dollars from traditional linear TV toward digital CTV, with linear spend declining while digital nonmobile spend that includes CTV keeps growing (EMARKETER).

Whether your organization marks the crossover in late 2025 or 2026 planning, the strategic point is the same: the streaming-side TV budget is now competing directly with, and in many plans overtaking, old linear-first assumptions (EMARKETER).

That does not mean linear is dead. It means the role is changing.

For many healthcare brands, the best current model is not “CTV instead of TV.” It is “CTV as the smarter TV layer.” Use linear where mass awareness still matters. Use CTV where targeting, controlled repetition, measurement, and post-impression actions matter more.

That is especially true when the media plan needs to work alongside search and social. A patient who sees a branded or disease-awareness spot on streaming TV often converts later through search, site visitation, or a provider conversation. If your team is already aligning paid search and regulated channel planning, our articles on FDA-compliant pharma PPC and the ultimate healthcare PPC guide show how those lower-funnel channels can capture the demand that CTV creates upstream.

How FDA fair balance applies to CTV ads

This is where some teams get into trouble.

CTV may feel like digital media from a buying and reporting standpoint, but for prescription drug promotion it still sits inside the television-format framework. FDA’s guidance on the major statement rule says that direct-to-consumer human prescription drug ads presented in television or radio format that state the drug name and its conditions of use must present the major statement relating to side effects and contraindications in a “clear, conspicuous, and neutral manner” (FDA guidance).

The FDA then gets more operational in its 2023 announcement of the final rule. For TV-format ads, the agency says the major statement should use consumer-friendly language, the audio should be at least as understandable as the rest of the ad, the risk information should appear concurrently in audio and text, the on-screen text should be displayed long enough to read easily, the text should be formatted so it can be read easily, and the ad should not include audio or visual elements that interfere with understanding the major statement (FDA announcement).

That is the practical fair-balance test for CTV creative.

If the benefits are cinematic, emotional, loud, fast, and visually reinforced, but the risk section becomes rushed voiceover over busy visuals with tiny supers, you do not suddenly become safer because the ad was bought programmatically. You just created a streaming version of the same old TV compliance problem.

In practice, healthcare marketers should treat the CTV major statement as needing comparable force to the benefit message: understandable audio, readable on-screen reinforcement, enough dwell time, and no competing design choices that bury the risk. If you want the longer design-and-content version of that principle, our guide to fair balance in pharma advertising goes deeper into what risk and benefit parity looks like in real execution.

The other misconception is that a URL, QR code, landing page, or support site can rescue a weak on-screen risk presentation. FDA’s broadcast advertising guidance makes clear that the major statement and adequate provision work together; adequate provision is not a substitute for presenting the product’s major risks in the ad itself (FDA broadcast guidance).

So yes, you can still use QR codes, vanity URLs, branded sites, and follow-up content. No, you should not think of them as a way to move core risk off the screen.

That same mindset shows up across other regulated channels too. If your team is also managing paid social or online video, our piece on FDA social media guidelines for pharma is a useful companion because the same underlying rule applies: if the medium cannot carry fair balance well, force-fitting the claim is usually the wrong move.

A 6-step CTV launch framework for pharma teams

The healthcare brands that win in CTV usually do not win because they found one magical platform. They win because they built an operating model that respects both media performance and medical-legal-regulatory review.

1) Audience strategy

Start with the audience, not the inventory.

For pharma, that usually means deciding whether the campaign is disease-state, branded DTC, caregiver, or adherence-focused. For MedTech, it may mean patient demand generation, procedure awareness, local market acceleration, or support for HCP-influenced journeys.

Then define what signals actually matter:

• First-party CRM or site audiences
• Condition-interest or health-intent segments
• Behavioral proxies
• Payer or access geography
• Lookalikes based on compliant data use
• Exclusions for pediatric or otherwise unsuitable contexts

This is also where patient vs. HCP logic matters. Even when the impression is on a household TV, the follow-on behavior may split between patient search, caregiver research, and provider discussion. If your messaging or KPI framework does not reflect that, the campaign will be harder to measure honestly.

2) Inventory and platform selection

Next, choose where the campaign should actually run.

Do not treat all CTV inventory as equal. There is a real difference between premium subscription ad tiers, broadcaster inventory, open-exchange supply, and FAST environments. Brand safety, content context, completion quality, and audience signal strength can vary widely.

For healthcare brands, inventory selection should answer five questions:

1. Does the platform support the audience inputs you need?
2. Does it allow sufficient household frequency control?
3. Does it provide the measurement outputs you need?
4. Can you build inclusion and exclusion lists tightly enough?
5. Is the content environment appropriate for a regulated healthcare message?

Programmatic CTV is where many teams overestimate efficiency and underestimate governance. If you are buying broadly, you need curated allowlists, sensitive-content exclusions, and extra caution around kids and family inventory, sensational news adjacency, or content that can distort the tone of a healthcare message.

3) Creative production with MLR involved early

Do not build the spot first and invite MLR at the end.

Healthcare CTV works best when legal, regulatory, medical, brand, and media teams agree early on the claim structure, the major statement approach, the visual pacing, and the number of approved creative variants. That is even more important in 2025 and 2026 as more brands test modular creative, interactive overlays, QR-based response paths, and AI-assisted variant generation.

The safest use of AI here is not fully autonomous creative. It is controlled variant development inside a pre-approved message architecture with human review and final MLR sign-off.

In practical terms:

• Approve a message hierarchy before editing
• Lock safety language early
• Decide whether 15s, 30s, or a mix is supportable
• Review readability and contrast in the risk section on real TV screens, not just laptops
• Test pace, audio intelligibility, and super timing before trafficking

4) Trafficking and pacing

Operational discipline matters more in CTV than many teams expect.

Set clear frequency caps. Separate awareness audiences from retargeting audiences. Break out geo priorities. Watch daypart and platform delivery. Confirm that companion or extension placements are consistent with the approved claim strategy.

A common mistake is letting broad delivery settings chase cheap impressions until the campaign over-serves narrow pockets of households. Another is trafficking multiple versions without a naming convention that allows learning later.

Your trafficking setup should make it easy to answer basic questions every week:

• Where did impressions actually land?
• How often did the same household see the ad?
• Which markets are underdelivering?
• Which creative variant is carrying the best completion and response mix?
• Are any placements too broad for the audience strategy or too risky for the brand?

5) Measurement and attribution

This is where CTV earns its keep.

The IAB’s measurement work exists because the category needs shared definitions for impression quality, reach, frequency, viewability, and attention across a fragmented supply environment (IAB guidance).

For healthcare, that means building a measurement stack that goes beyond video completions. Strong connected TV healthcare programs usually track some combination of:

• Incremental reach against linear or other video
• Household frequency
• Site visits and qualified landing-page engagement
• Search lift on branded and disease terms
• Brand lift or recall studies
• Audience extension performance on mobile and desktop
• CRM progression or lead quality for MedTech
• Script lift, patient-start proxies, or matched commercial outcomes where legally and operationally feasible

If your team needs a more complete framework for stitching channel metrics to business outcomes, our healthcare marketing attribution guide covers the broader system design behind this.

6) Optimization

Optimization in CTV is not just lowering CPMs. In healthcare, that is often the wrong goal.

The right optimization loop asks:

• Which audiences respond without waste?
• Which placements drive outcome quality, not just cheap delivery?
• Which markets show stronger downstream search or site engagement?
• Which creative version sustains attention without hurting readability or compliance?
• Where should the campaign expand through retargeting or audience extension?

This is also where newer CTV capabilities can help. Interactive units, shoppable response paths, sequential messaging, and audience extension can all improve performance when they are wrapped in a compliant message system. Addressable households and retargeting can be powerful, but only when the privacy model, consent posture, and approved claims are clear.

Platform breakdown: where healthcare brands actually buy

No single platform is universally best. The right mix depends on audience definition, risk tolerance, market coverage, and reporting needs.

Directional note: CPM ranges below are planning estimates, not guarantees. Actual pricing changes with buying method, audience density, creative format, seasonality, and negotiated access.

A few practical takeaways:

• Premium subscription inventory usually gives stronger environment control and often higher CPMs.
• FAST environments can be very efficient and very useful, but they demand tighter inventory governance.
• YouTube on the TV screen can work well, but healthcare brands should approach it with stricter channel and content controls than they would use in a general consumer campaign.
• Roku is often valuable as both a media environment and an audience extension layer.

The best healthcare plans usually blend premium inventory with selective efficiency inventory rather than choosing one camp exclusively.

Compliance considerations beyond the ad itself

Most healthcare teams think about compliance at the creative level first. They should. But CTV compliance is also a media-operations issue.

FDA and fair balance

The obvious rule is still the most important one: if it is a prescription drug TV-format ad, risk presentation has to work in the ad itself. That means audio clarity, readable visual support, and no distracting elements during the major statement (FDA announcement).

FTC and truth-in-advertising expectations

For disease awareness, OTC, wellness, and many MedTech messages, FTC-style substantiation logic still matters. Claims need to be supportable, not just emotionally persuasive. Interactive CTV units do not lower that bar.

State privacy laws and data use

Audience construction and audience extension can trigger privacy-review questions, especially when teams try to combine health-adjacent data, CRM uploads, or retargeting logic. That does not mean CTV is off-limits. It means governance has to be documented.

Kids-content avoidance

This deserves special emphasis. A lot of streaming inventory sits near family or youth-oriented programming. Even when a platform itself is acceptable, the surrounding content mix may not be. Healthcare advertisers need explicit exclusion rules for kids and highly sensitive environments, especially in open or semi-open programmatic supply paths.

Inventory approvals and auditability

If your team cannot explain where impressions ran, what exclusions were applied, how frequency was controlled, and which creative version served to which audience, the campaign is not operationally mature enough for regulated healthcare.

Measurement and attribution: how CTV proves value

This is where the conversation moves from “Did the ad run?” to “Did the ad change anything?”

The IAB’s measurement guidance exists because CTV still suffers from fragmented standards and inconsistent signal quality across platforms, which means advertisers need disciplined definitions for reach, frequency, impressions, and attention if they want useful cross-platform learning (IAB guidance).

For healthcare brands, the most useful measurement stack usually works in layers:

Layer 1: Delivery quality

Start with the basics:

• Impressions
• Completed views
• Reach
• Household frequency
• Cost efficiency by platform and market

These numbers tell you whether the media ran properly. They do not tell you whether it mattered.

Layer 2: Response signals

Then look at the near-term actions CTV often drives:

• Branded search lift
• Disease-term search lift
• Site visits
• Time on site and engaged sessions
• QR or vanity URL response
• Visits to support or savings pages

This is where CTV often proves more useful than traditional TV because the response shows up quickly in digital behavior.

Layer 3: Brand and consideration lift

For awareness campaigns, brand lift matters. Did recall improve? Did message association improve? Did consideration move in the right audience?

This is particularly useful for new indication launches, disease-state education, and MedTech brand building where the commercial outcome may lag the media impression by weeks or months.

Layer 4: Commercial outcomes

This is the endgame.

For pharma, the strongest model is closed-loop analysis that connects CTV exposure to downstream commercial signals such as script lift or patient-start proxies where legally and operationally possible. For MedTech, that may mean lead quality, referral movement, consult requests, procedure growth in targeted markets, or account progression.

If you stop at platform dashboards, you will underrate the channel. If you insist on last-click logic, you will misread it completely.

CTV is usually most powerful when measured as an influence channel inside a broader healthcare attribution framework. That is exactly why we recommend connecting CTV analysis to search, site, CRM, and offline outcome systems rather than judging it in isolation.

Common pitfalls in connected TV healthcare campaigns

Most underperforming healthcare CTV programs fail in predictable ways.

1. Treating CTV like digital display on a big screen

CTV may be bought digitally, but the creative burden is still television-level. Weak visuals, rushed pacing, or text that only looks readable on a laptop will hurt both response and compliance.

2. Treating CTV like legacy TV with better reporting

The opposite mistake is just as common. Teams port a linear spot into CTV, buy broad inventory, and then ignore audience strategy, frequency control, and platform-level learning. That wastes the best parts of the channel.

3. Letting media teams pick inventory before compliance guardrails exist

In healthcare, the inventory strategy and the compliance strategy should be built together. If you buy first and ask questions later, you create avoidable risk.

4. Overvaluing cheap CPMs

The cheapest inventory is often the messiest inventory. Lower CPMs can be good. Lower-quality supply usually is not.

5. Using a single KPI

If the only success metric is completion rate, you will miss business value. If the only success metric is scripts, you will miss upper-funnel influence. Healthcare CTV needs layered measurement.

6. Ignoring cross-channel behavior

CTV often creates demand that search, branded site visits, CRM journeys, or field conversations capture later. A siloed read will make the channel look weaker than it is.

7. Forgetting that kids and sensitive content exclusions need active management

This is one of the easiest operational misses in programmatic CTV and one of the most avoidable.

FAQ

Is connected TV compliant for pharma advertising?

Yes, connected TV can absolutely be compliant for pharma advertising. The key is remembering that streaming TV inventory does not remove the FDA standards that apply to prescription drug television-format ads, including clear, conspicuous, and neutral presentation of the major statement (FDA guidance, FDA announcement).

Is CTV replacing linear TV for healthcare brands?

Not entirely. Linear still matters for broad reach and major live moments. But healthcare and pharma budgets are clearly shifting toward digital and CTV-style planning as marketers prioritize targeting and measurement (EMARKETER).

What is the biggest compliance mistake in CTV advertising pharma campaigns?

Thinking that the medium changes the standard. The most common mistake is still weak fair balance: strong benefits, weak risk presentation, rushed major statements, or distracting visuals during risk communication.

Which CTV platforms are best for healthcare brands?

Usually a mix. Hulu, Roku, Peacock, Disney inventory, Netflix Ads, Tubi, Pluto, and YouTube CTV can all work. The right answer depends on your audience definition, content suitability needs, and measurement requirements.

How should pharma teams measure CTV success?

Start with reach and frequency, then add search lift, site visitation, brand lift, and where feasible script lift or downstream matched outcomes. CTV is best measured as part of a broader attribution system, not as a standalone dashboard.

Can MedTech brands use connected TV effectively too?

Yes. MedTech often benefits from CTV in regional launches, procedure awareness, patient demand generation, and household-level targeting around priority markets. The creative and KPI structure may differ from branded Rx, but the channel logic is still strong.

Is programmatic CTV safe for regulated healthcare brands?

It can be, but only with disciplined platform selection, allowlists, exclusions, frequency control, and reporting. Open access without governance is where many brand-suitability problems begin.

Why XDS Health is built for this channel

CTV works best when channel strategy, creative systems, UX thinking, analytics, and compliance discipline are all in the same room.

That is exactly where healthcare teams tend to struggle. One group owns media. Another owns brand. Another owns MLR. Another owns analytics. The result is usually a channel that is either overcontrolled and slow, or fast and risky.

XDS helps healthcare and life sciences brands close that gap.

We build regulated digital ecosystems where performance and compliance are not treated like opposing forces. That means audience strategy grounded in real journeys, creative systems that survive review, measurement frameworks that connect awareness to action, and channel planning that works across CTV, search, social, sites, and downstream conversion environments.

If your team is exploring connected TV healthcare strategy, reworking a CTV advertising pharma launch, or trying to make streaming TV measurable without creating a compliance mess, XDS can help you build the plan before media dollars start leaking.

Want a smarter healthcare CTV program?

Talk to XDS Health about audience strategy, compliant creative systems, media architecture, and measurement design that turns streaming TV into a channel your brand team can actually trust.